1
2
3Scientific
*Correspondence Author: Kadhum J. Mowayeiz,
Verify the utility of measuring prostate cancer antigen 3 (PCA3) and serum PSA levels in the diagnosis of prostate cancer.
This case-control study conducted from March 2017 to November 2018. It consisted of 140 men subjects with age rang (40–85 years); 70 prostate cancer patients group included (35 patients with newly diagnosed Pca and 35 prostate cancer patients under hormonal therapy treatment (HT-Pca) and 35 patients with benign prostate hyperplasia (BPH) and 35 healthy men age matched normal control.
The PCA3 and serum total and free PSA were measurement by using ELISA technique in patients and healthy controls. The results revealed that the mean values of PCA3, serum total and free PSA and the prostate Specific antigen density (PSAD) of prostate cancer patients and hormonal therapy group were significantly higher compared with healthy controls (all p-value <0.001) the mean of the percentage free/total PSA Ratio were significantly lower than those of benign prostate hyperplasia and healthy controls.
The diagnostic value of PCA3 is relatively higher, as it of both sensitivity and specificity; increased serum PCA3 values cannot be detected in presence of other cancers. PCA3 level in serum can discriminate early Pca from healthy controls, indicating its diagnostic value for the early-stage Pca.
Prostate cancer antigen, prostate cancer, marker, benign prostate hyperplasia, stage